A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth.

The most prevalent lung cancer, non-small cell lung cancer (NSCLC) has receptors for vasoactive intestinal peptide (VIP). Here the effects of a VIP antagonist (VIP-hyb) on NSCLC growth were investigated. In vivo, when VIPhyb (10 micrograms, s.c.) was daily injected into nude mice, xenograft formatio...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Moody, T W, Zia, F, Draoui, M, Brenneman, D E, Fridkin, M, Davidson, A, Gozes, I
Formato: Artigo
Idioma:Inglês
Publicado em: 1993
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC46507/
https://ncbi.nlm.nih.gov/pubmed/8389448
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados